To the Editor: Patients' experiences with dermatologic procedures might be influenced most substantially by pain or lack thereof; therefore, any techniques that minimize pain are tremendously important. The pain associated with injection of local anesthetic is often the only pain felt during these procedures. Investigators have described various methods to decrease injection pain, such as buffering and warming the anesthetic, 1,2 using finer needles, 3 injecting slowly, 4 and altering insertion angle. 5 We developed a technique to minimize injection pain whereby the needle tip is inserted parallel to the skin into the superficial dermis. Herein, we examined lidocaine injection using this technique.
This IRB-exempted study was conducted on mentally competent Mohs surgery patients with head and neck tumors over the course of 3 months. The anesthetic used was 0.5% lidocaine containing 1:200,000 epinephrine buffered 1:10 with 8.4% sodium bicarbonate. Anesthetic was injected using 30-gauge needles on 3-mL syringes and was always performed by the same investigator. Constant, light pressure was placed on the plunger before and during insertion of the needle, resulting in the slow extrusion of anesthetic, taking 2 minutes to empty the first syringe. The needle was oriented bevel-down parallel to the skin and with slight downward pressure was slowly advanced into the superficial dermis (Fig 1) . Upon skin blanching, needle movement ceased, and anesthetic solution was injected slowly, allowing for gradual infiltration. The needle tip was kept within the wheal when advancing the needle to anesthetize a broader area. Following injection, patients described and quantified pain felt during needle insertion and anesthetic infiltration on the 10-point visual analog scale (VAS), in which 0 represents no pain and 10 represents the worst pain imaginable. Sudden sharp pain was attributed to needle insertion, while slow burning and stinging pain was attributed to lidocaine infiltration. P values were calculated using 2-tailed z-scores for statistical significance.
This study included 146 patients (98 men and 48 women) with a mean age of 66.6 years (standard deviation, 16.0 years) divided into groups based on injection site (head, scalp, or neck). Sixty-six patients injected on the face (62.3%), 13 on the scalp (54.2%), and 9 on the neck (56.3%) reported no pain during needle insertion (Fig 2) . The mean VAS score for the face was 0.66 (standard error of the mean [SEM] 0.11), for the scalp 0.96 (SEM, 0.25), and for the neck 0.82 (SEM 0.21). Only 4% of patients felt pain from lidocaine infiltration, with a mean VAS score of 1.6 (data not shown).
These data suggest this technique might be a superior method for achieving painless injections of lidocaine without the need for extra devices. Most patients reported no pain. Interestingly, mean VAS scores were \1 out of 10, with previous studies showing scores of $3. 4, 5 We hypothesized that minimal needle insertion allows for lidocaine to diffuse and anesthetize dermal nerves before the needle stimulates C fibers, resulting in decreased pain. Furthermore, buffered lidocaine was injected slowly to minimize pain with fluid infiltration. Further studies with controlled comparisons against established techniques are needed to establish superiority; however, this is a large step toward a pain-free experience during dermatologic procedures. Association between bullous pemphigoid and psoriasis: A case-control study
To the Editor: Although the coexistence of bullous pemphigoid (BP) and psoriasis has been described, the association between the two entities is still to be established. 1 The prevalence rate of psoriasis among patients with BP is inconsistent in different BP cohorts. 2, 3 Little is known about differences in demographics, clinical presentation, immunopathologic features, management, and prognosis between patients with isolated BP and those with coexisting BP and psoriasis.
We sought to compare the prevalence of psoriasis in an immunopathologically validated large cohort of BP patients relative to age-, sex-, and ethnicitymatched control subjects. Our second endpoint was to characterize the subgroup of patients with concomitant BP and psoriasis relative to patients with BP without psoriasis.
The study was designed as a case-control study. The case group comprised all consecutive patients with a new diagnosis of BP between January 2000 and December 2015 in Rambam Health Care Campus, Haifa, Israel. BP was diagnosed as a blistering disease of the skin with the typical established immunopathologic criteria. 4 The diagnosis of psoriasis was based on clinical manifestation with and without histopathologic analysis. The control group consisted of patients who underwent laparoscopic appendectomy and excision of nonmelanoma skin lesions in our institution. Four to 5 control patients were randomly selected for each patient with BP.
Our study consisted of 287 patients newly diagnosed with BP between 2000 and 2015 and 1373 age-, sex-, and ethnicity-matched control subjects. The prevalence rate of psoriasis was greater in patients with BP than in control subjects (5.2% vs 1.2%, respectively; odds ratio, 4.4; 95% confidence interval, 2.2-8.9; P \ .0001). The association was prominent in patients younger than 80 years of age, and its strength was remarkably higher among subjects younger than 60 years. This association was also significant among both sexes and in individuals of Jewish ancestry (Table I) .
Psoriasis preceded the diagnosis of BP in all patients with both diseases, by a mean duration of 25.2 6 18.6 years. Patients with coexisting BP and psoriasis were significantly younger at presentation relative to those with isolated BP (68.5 6 13.7 vs 78.0 6 11.9 years, respectively; P ¼ .003), and the mucosal surfaces were more frequently involved (33.3% vs 15.4%, respectively), with a near-significant difference (P ¼ .077) (Table II) . There was a tendency to treat patients with coexisting BP and psoriasis with adjuvant immunosuppressants more frequently (46.7% vs 20.2%; P ¼ .016) (Table II) .
Psoriasis vulgaris was the most prevalent type of psoriasis (93.3%) in our cohort. Six (40%) of the patients were previously treated with phototherapy and/or climatotherapy for psoriasis, but none of them developed BP during these treatments.
The main limitation of our study was the small sample of patients with coexisting BP and psoriasis.
In conclusion, we report a significant association between BP and psoriasis. Psoriasis preceded BP in all patients having the 2 diseases concomitantly. Relative to those with isolated BP, patients having both diseases were significantly younger. This may be due to the antigenicity of the basement membrane in psoriasis patients being altered at a younger age, stimulating antibasement membrane autoantibody formation and BP development earlier in life. 5 Patients with both entities were treated more frequently with adjuvant immunosuppressants, possibly to avoid high-dose corticosteroids for long durations in psoriatic patients.
